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OBJECTIVE—Progressive ﬁbrosis in the diabetic kidney is
driven and sustained by a diverse range of proﬁbrotic factors.
This study examines the critical role of microRNAs (miRNAs) in
the regulation of the key ﬁbrotic mediators, TGF-1 and TGF-2.
RESEARCH DESIGN AND METHODS—Rat proximal-tubular
epithelial cells (NRK52E) were treated with TGF-1 and TGF-2
for 3 days, and expression of markers of epithelial-to-mesenchy-
mal transition (EMT) and ﬁbrogenesis were assessed by RT-PCR
and Western blotting. The expression of miR-141 and miR-200a
was also assessed, as was their role as translational repressors of
TGF- signaling. Finally, these pathways were explored in two
different mouse models, representing early and advanced dia-
betic nephropathy.
RESULTS—Both TGF-1 and TGF-2 induced EMT and ﬁbro-
genesis in NRK52E cells. TGF-1 and TGF-2 also downregu-
lated expression of miR-200a. The importance of these changes
was demonstrated by the ﬁnding that ectopic expression miR-
200a downregulated smad-3 activity and the expression of matrix
proteins and prevented TGF-–dependent EMT. miR-200a also
downregulated the expression of TGF-2, via direct interaction
with the 3 untranslated region of TGF-2. The renal expression
of miR-141 and miR-200a was also reduced in mouse models
representing early and advanced kidney disease.
CONCLUSIONS—miR-200a and miR-141 signiﬁcantly impact on
the development and progression of TGF-–dependent EMT and
ﬁbrosis in vitro and in vivo. These miRNAs appear to be
intricately involved in ﬁbrogenesis, both as downstream media-
tors of TGF- signaling and as components of feedback regula-
tion, and as such represent important new targets for the
prevention of progressive kidney disease in the context of
diabetes. Diabetes 60:280–287, 2011
D
iabetic nephropathy is characterized by the pro-
gressive accumulation of extracellular matrix
(ECM) in basement membranes, the glomerular
mesangium, and peritubular interstitium, which
leads to scarring and ultimately nephron dropout. Recent
data have suggested an important role for speciﬁc micro-
RNAs in enhancing ﬁbrogenic signaling and sustaining
proﬁbrotic phenotypes (1) that potentially contribute to
the development and progression of a number of diseases
(2). MicroRNAs (miRNAs) are short, single-stranded RNA
molecules that interact with the 3 untranslated region
(UTR) of mRNAs to regulate gene expression. This usually
occurs by repression of protein translation via a mecha-
nism that involves incomplete base pairing with the 3UTR
of target mRNAs, or by causing target sequences to
become unstable and degraded sooner (2,3), thereby caus-
ing protein expression to be downregulated.
In the kidney, renal ﬁbrosis is initiated and sustained by
a number of different prosclerotic factors. Among the most
important of the prosclerotic factors appears to be TGF-
(4,5), which stimulates the expression of matrix proteins
and triggers tubular epithelial-to-mesenchymal transition
(tubular EMT) in tubular cells. In the kidney, TGF- is
expressed in three different isoforms. Each isoform in-
duces ﬁbrogenesis in renal cells in vitro (6), possibly
acting through the same receptors. However, differential
effects on immune function and development have been
reported (7,8). For example, deletion of TGF-1 results in
widespread distribution and immunomodulatory effects
not seen with TGF-2. In the streptozotocin model of
diabetes, the expression of TGF-2 is markedly increased
in the kidney, paralleling renal ECM accumulation early in
disease (8,9). By contrast, TGF-1 protein levels remain
unchanged during this period despite increased mRNA
levels (9). Consequently, recent studies have focused on
the antiﬁbrotic potential of selectively targeting TGF-2
for the prevention of progressive renal disease (10,11).
A number of different factors are thought to alter the
expression of TGF-2 in the kidney, including miRNAs. In
particular, 3UTR of TGF-2 contains a target site for
miR-141/200a. Moreover, TGF-1 has been shown to reg-
ulate the miR-200 family in a renal cell line (12). In this
study, we investigate the role of miR-200a and its closely
related family member, miR-141, as regulators of TGF-2
and ﬁbrogenesis both in vitro and in vivo, using two animal
models of renal ﬁbrosis, representing earlier- and later-
stage kidney disease.
RESEARCH DESIGN AND METHODS
In vitro studies—cell culture. The rat kidney tubular epithelial cell line
(NRK52E) was obtained from the American Tissue Culture Collection (Rock-
ville, MD) and maintained in Dulbecco’s modiﬁed Eagle medium containing
10% serum and 25 mmol/l glucose as previously described. For experimental
treatments, serum was reduced to 2%.
Drugs and antibodies. Recombinant human TGF-1, TGF-2, normal goat
IgG, and TGF-2 neutralizing antibody were from R&D systems (Minneapolis,
MN) and used at speciﬁed concentrations. Typically, 24 h after cells were
seeded, the medium was replaced with fresh medium containing 2% serum
with or without the treatment, and cells were incubated a further 3 days. For
Western blotting, primary antibodies were collagen I and -smooth muscle
actin (SMA) (1:2,000; Dako), E-cadherin (1:2000; Becton Dickinson), and
From the
1Diabetes Division, JDRF Danielle Alberti Memorial Centre for
Diabetes Complications, Melbourne, Australia; and the
2Muscle Biology and
Therapeutics, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Corresponding author: Phillip Kantharidis, phillip.kantharidis@bakeridi.
edu.au.
Received 28 June 2010 and accepted 1 October 2010. Published ahead of
print at http://diabetes.diabetesjournals.org on 15 October 2010. DOI:
10.2337/db10-0892.
© 2011 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
280 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.org-actin (1:10,000; Abcam) and secondary antibodies were goat anti-mouse or
goat anti-rabbit HRP conjugated (1:2,000; Dako).
RNA extraction and real-time PCR. Gene expression was analyzed by
real-time (RT)-PCR, using the TaqMan system based on real-time detection of
accumulated ﬂuorescence (ABI Prism 7500; Perkin-Elmer, Foster City, CA).
Fluorescence for each cycle was quantitatively analyzed by an ABI Prism 7500
Sequence Detection System (Perkin-Elmer). To control for variation in the
amount of DNA that was available for PCR in the different samples, gene
expression of the target sequence was normalized in relation to the expression
of an endogenous control, 18S rRNA (18S rRNA TaqMan Control Reagent kit,
ABI Prism 7500; Perkin-Elmer). Details of primers and TaqMan probes for
these genes have been previously reported (4). Each experiment was con-
ducted in four or six replicates. Results were expressed relative to control
(untreated) cells, which were arbitrarily assigned a value of 1.
miRNA assay. For miRNA analysis, cDNA synthesis and RT-PCR assays were
performed using TaqMan miRNA assays as per manufacturer’s recommenda-
tions (Applied Biosystems, Foster City, CA). Experimental groups were in
replicates of six and normalized to Sno135 or U87 for mouse and rat samples,
respectively.
Transfection of miRNA precursors. NRK52E cells were seeded at 3  10
4
cells per well in 12-well plates. The following day, medium was replaced with
OptiMEM (Invitrogen), and cells were transfected with premiRNAs (Applied
Biosystems) at 100 nmol/l ﬁnal concentration using Oligofectamine (Invitro-
gen). In each case premiRNA negative controls were used at the same
concentration. Cells were harvested three days posttransfection. Under these
conditions, transfection efﬁciency was high, typically with 5–10,000-fold
higher miRNA expression observed in transfected cells when compared with
endogenous levels.
TGF-23 UTR-luciferase reporter analyses. For transfection, NRK52E
cells were seeded 1  10
5 cells per well in 6-well plates the day before
transfection (4). The TGB-23 UTR was cloned into the pRL reporter vector
(Promega) by PCR and represents the entire 352 nucleotides of the 3UTR.
The mutant TGF-23 UTR, synthesized (GenScript), was identical to the
wild-type sequence except for the seed region, where the complementary
sequence was used.
pRL-reporter plasmids (0.5 g/ml), CMV-galactosidase construct, and
miRNAs were cotransfected using Lipofectamine 2000 (Invitrogen) in Opti-
MEM medium. Cells were harvested 48 h posttransfection using the Dual-
Luciferase reporter assay system (Promega), and luciferase and galactosidase
assays were performed as per manufacturer’s recommendations. All experi-
ments were performed in triplicate, and each experiment was repeated at least
twice.
SMAD3 activity. The CAGA12-luciferase reporter was used to assess SMAD3
activity. The construct contains the luciferase gene, the expression of which
is driven by a promoter with CAGA boxes (CAGA12) to which activated
SMAD3 binds (13). Transfection experiments and luciferase assays were
performed as for the 3UTR assays.
TGF-2 ELISA. The TGF-2 ELISA (R&D Systems) was used to determine
the total level of TGF-2 in acid-activated cell culture supernatants as per the
manufacturer’s recommendations.
Western blot analysis. Whole-cell lysates that contained 10–50 g of protein
were subjected to 10–12% SDS-PAGE and transferred onto polyvinylidene
ﬂuoride membranes by semidry transfer. Membranes were blocked in 5% skim
milk/Tris-buffered saline with Tween for1ha troom temperature. All primary
and secondary antibody incubations were for1ha troom temperature.
Detection was by chemiluminescence and images captured on the XRS
Chemidoc system (BioRad) and analyzed by Quantity One software (BioRad).
In vivo studies. To explore the relationship between miR-200a and the
development and progression of ﬁbrotic kidney disease, renal ﬁbrogenesis
was studied in two animal models of renal ﬁbrosis, representing earlier and
later renal stage kidney disease, respectively. Early renal changes were
examined in apoE knockout mice rendered diabetic by ﬁve daily intraperito-
neal injections of streptozotocin (55 mg/kg) as previously described (14) and
compared with apoE KO mice that received vehicle (citrate buffer) alone (n 
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FIG. 1. TGF-2 induces EMT-like changes in proximal tubular epithelial cells. A: NRK52E cells were cultured in the presence of TGF-2 (10 ng/ml,
3 days). Light microscopy images (20) demonstrate that TGF-2 causes a loss of the typical epithelial morphology to larger and more irregular
shaped cells typical of the myoﬁbroblast phenotype. B: After treatment with TGF-2 (10 ng/ml, 3 days), gene expression levels were assessed by
real-time QPCR. A signiﬁcant increase was observed in the expression of proﬁbrotic factors (TGF-1, CTGF), ﬁbrotic genes (SMA, ﬁbronectin
[Fib], collagen [Col] I and IV), and PAI-1, but E-cadherin (E-cad) was signiﬁcantly reduced (*P < 0.05 compared with control). C: Western analysis
demonstrated that SMA and Col I were both signiﬁcantly elevated at the protein level after TGF-2 treatment, while E-cadherin was decreased.
D: The results from the Western analysis in C are shown as a graph (*P < 0.05 compared with control).
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diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 2818/group). We have previously described that 10 weeks of diabetes is associ-
ated with all of the early changes of diabetic nephropathy including mi-
croalbuminuria, renal hypertrophy, hyperﬁltration, and basement membrane
(14). In the second model, c57bl6 mice were randomized to receive oral
gavage with adenine (1 mg/kg/day) or vehicle (0.5% methylcellulose) for four
weeks (n  4/group). This results in marked tubulointerstitial ﬁbrosis and
nephron dropout, consistent histologically with changes seen in more ad-
vanced chronic kidney disease (15).
Immunohistochemistry. Four-micrometer parafﬁn kidney cortex sections
were used for immunohistochemical analyses as previously described (16).
Primary antibodies used were collagen IV, ﬁbronectin, and SMA (1:800;
Southern Biotechnology, Birmingham, AL). Secondary antibodies were used
as previously described (16). Finally, sections were counterstained with
Mayer’s hematoxylin, dehydrated, and mounted.
Statistical analysis. Values are shown as means  SEM unless otherwise
speciﬁed. Statview (Brainpower, Calabasas, CA) was used to analyze data by
unpaired Student t test or by ANOVA and compared using Fisher least
signiﬁcant differences post hoc test. Nonparametric data were analyzed by
Mann-Whitney U test. P values  0.05 were considered signiﬁcant.
RESULTS
TGF-2 induces expression of EMT and ﬁbrogenesis.
Exposure of NRK52E cells to TGF-2 (10 ng/ml) for 3 days
resulted in a morphological and phenotypic transition
characteristic of EMT (Fig. 1A) associated with reduced
expression of the epithelial marker, E-cadherin; increased
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FIG. 2. TGF-1-induced ECM gene and TGF-2 expression changes in proximal tubular epithelial cells. A: NRK52E cells (Dulbecco’s modiﬁed
Eagle medium, 25 mmol/l glucose, 2% serum) were treated with TGF-1 (10 ng/ml, 3 days), and the expression of several genes was assessed by
real-time QPCR. Signiﬁcant changes are indicated (*P < 0.05 compared with control). B: The change in expression of TGF-1 and TGF-2 genes
was assessed by real-time QPCR, and signiﬁcant changes are indicated (*P < 0.0005 compared with control). C: TGF-2 proteins levels were
measured by ELISA and expressed as pg/mg (*P < 0.0005 compared with control). D: NRK52E cells were incubated with either control IgG (1
g/ml) or TGF-2-speciﬁc neutralizing antibody (1 g/ml) for 1 h, and then TGF-1 was added (10 ng/ml). Cells were harvested 3 days later and
subjected to real-time QPCR analysis. The TGF-2 antibody prevented the increased expression of SMA, Collagen I, and ﬁbronectin that is
induced by TGF-1, compared with the IgG control antibody (*P < 0.05 compared with control). E: Cells were then treated with TGF-1 (10 ng/ml,
3 days) in the presence or absence of SB432542, the TGF-2 receptor inhibitor. Real-time QPCR analysis conﬁrmed that the gene expression
changes induced by TGF-1 are attenuated by SB432542 (*P < 0.05 and #P < 0.001 compared with control).
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FIG. 3. TGF-1-induced changes in miRNA expression. A: NRK52E cells were cultured in the presence of TGF-1 (10 ng/ml, 3 days) before miRNA
expression levels were assessed by real-time QPCR. A signiﬁcant decrease was observed in miR-200a but not in miR-141 (*P < 0.03 compared with
control). B: SB432542 also attenuated the TGF-1-induced reduction of miR-200a (*P < 0.02 compared with control). C: Treatment of NRK52E
cells with TGF-2 (10 ng/ml, 3 days) also caused reduction in the expression of miR-200a, miR-200b, and miR-200c (*P < 0.05 compared with
miR-control).
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and increased expression of ECM proteins, ﬁbronectin,
collagen I, and collagen IV (Fig. 1B). TGF-2 also induced
the expression of TGF-1 and the expression of PAI-1, a
classical marker of TGF-1 signaling (Fig. 1B). These
changes in expression were also observed at the protein
level (Fig. 1C and D).
TGF-1 induces TGF-2 and ﬁbrogenesis. Treatment
of the NRK52E cells with TGF-1 (10 ng/ml, 3 days) also
resulted in EMT and associated changes in gene expres-
sion (Fig. 2A). TGF-1 was also able to induce its own
expression (Fig. 2B) and that of TGF-2 at a gene (Fig. 2B)
and protein level (Fig. 2C). To explore the functional role
of TGF-2 changes induced by TGF-1, a neutralizing
antibody speciﬁc for TGF-2 was added to NRK52E cells
followed by TGF-1 treatment. This attenuated the induc-
tion of EMT and subsequent ﬁbrogenesis associated with
TGF-1 treatment (Fig. 2D). EMT was also blocked by the
TGF- type 1 receptor antagonist SB431542 (Fig. 2E), as
was the induction of TGF-2.
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FIG. 4. miR-200a represses the expression of ECM proteins. A: NRK52E cells were transfected with miR-200a (100 nmol/l), and RNA was
harvested after 3 days for real-time QPCR analysis. miR-200a resulted in signiﬁcantly decreased expression of several ECM proteins including
SMA, collagen (Col) I and IV, and ﬁbronectin (Fibr) (*P < 0.05 compared with control transfected cells). Expression of TGF-2 was also
signiﬁcantly decreased as was PAI-1, which is downstream of the TGF- signaling pathway. The expression of E-cadherin (E-cad) was signiﬁcantly
elevated. B: Western analysis demonstrated a signiﬁcant decrease in SMA and collagen I by miR-200a, consistent with the RNA expression
analysis (*P < 0.05 compared with control transfected cells). The Westerns were quantiﬁed and also shown in graph format below the Western
blots (*P < 0.05 compared with control). C: NRK52E cells were cotransfected with the p(CAGA)12 SMAD3 activity reporter construct, a
-galactosidase construct, and miR-200a. Four h later, the cells were treated with TGF-1, and cells were harvested after 3 days. TGF-1 resulted
in increased SMAD3 activity with miR-C, which was strongly inhibited by miR-200a (*P < 0.00005 compared with miR-C control; #P < 0.0005
compared with miR-C with TGF-1; $P < 0.002 compared with miR-200a control). D: Western analysis of phospho-SMAD3 and total SMAD3 levels
in miR-200a-transfected NRK52E demonstrating reduced SMAD3 phosphorylation relative to total SMAD3 protein (*P < 0.05 compared with
miR-C control). The Westerns were quantiﬁed and shown in graph format (*P < 0.05 compared with miR-C).
B. WANG AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 283TGF-1 and TGF-2 downregulate the expression of
miR-200a. Treatment with TGF-1 led to decreased ex-
pression of miR-200a (Fig. 3A) and miR-200b/c as previ-
ously reported (17). This downregulation of miR-200a by
TGF-1 was prevented by the TGF- type 1 receptor
antagonist SB431542 (Fig. 3B). NRK52E cells exposed to
TGF-2 (10 ng/ml) for 3 days also reduced the expression
of miR-200a, miR-200b, and miR-200c (Fig. 3C), of which
the decrease in miR-200a was the most pronounced.
Neither TGF- isoform resulted in a signiﬁcant change in
miR-141 expression, when compared with untreated cells.
miR-200a downregulates the expression of ECM pro-
teins. Ectopic expression of miR-200a after transfection
with premiR-200a resulted in decreased expression of
several ECM genes, including collagen I and IV and
ﬁbronectin, compared with premiRNA-control transfected
NRK52E cells (Fig. 4A). Some of these changes in ECM
protein expression were also observed at the protein level
(Fig. 4B). miR-200a also caused reduced expression of the
mesenchymal marker, SMA, and increased expression of
the epithelial marker, E-cadherin mRNA levels (Fig. 4A),
consistent with previous reports that the miR-200 family
targets the transcriptional repressors of E-cadherin, ZEB1,
and ZEB2 (12,18–21). Finally the expression of PAI-1, a
downstream target of TGF- signaling, was also decreased
(Fig. 4A).
Because the expression of many ﬁbrotic genes is Smad3
dependent (22), we also investigated whether SMAD3
activity can be modulated by miR-200a. Interestingly,
transfection with miR-200a was able to attenuate SMAD3
activity by 50% in the absence of exogenous TGF-1 and
totally abolished the activation of SMAD3 in the presence
of TGF-1 (Fig. 4C). This is also observed at the level of
SMAD3 phosphorylation, which is reduced relative to total
SMAD3 (Fig. 4D).
miR-141 downregulates the expression of ECM pro-
teins. miR-141 shares the same seed sequence as miR-
200a (Fig. 5A). To study the ﬁbrogenic actions of miR-141,
NRK52E cells were transfected with miR-141 and changes
in gene expression were compared with premiRNA-con-
trol transfected NRK52E cells. As with miRNA-200a, miR-
141 also reduced the expression of collagen I, ﬁbronectin,
SMA, and TGF-2 and increased the expression of E-
cadherin (Fig. 5B).
Both miR-141 and miR-200a repress the expression of
TGF-2. The expression of TGF2 was also signiﬁcantly
decreased in miR-200a transfected cells (Fig. 4A). As
miR-200a and TGF-23 UTR share the same seed se-
quence as shown (Fig. 5A), we further investigated
whether TGF-2 is the direct target of miR-200a for
translational repression. In these experiments we used
luciferase reporter constructs incorporating a wild-type or
mutant 3UTR of TGF-2 in which the sequence corre-
TGF-β2 wt-3’UTR  5’ AGAGCCUUGGUUCAUCAGUGUUA 
miR-141          3’  GGUAGAAAUGGUCUGUCACAAU 
miR-200a         3’  UGUAGCAAUGGUCUGUCACAAU 
TGF-β2 mut-3’UTR 5’ AGAGCCUUGGUUCAUGUCACAAA
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FIG. 5. miR-141a shares the same seed sequence with miR-200a and
represses the expression of ECM proteins. A: Alignment of the miR-
141/200a sequences and the targeted area of the 3UTR of TGF-2
(http://www.targetscan.org). Also shown is the altered sequence of the
mutant 3UTR of TGF-2. B: Proximal tubular cells were transfected
with either miR-control or miR-141 (100 nmol/l), and the expression of
certain genes was assessed by real-time QPCR. As with miR-200a,
miR-141 was able to signiﬁcantly reduce the expression of SMA,
ﬁbronectin (Fibr), and collagen I (Col I) and resulted in increased
expression of E-cadherin (E-cad) (*P < 0.05 compared with control).
The expression of TGF-2 was also signiﬁcantly reduced.
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FIG. 6. The TGF-23 UTR is regulated by miR-141/200a. A: NRK52E
cells were transfected with TGF-23 UTR luciferase reporter plasmid
(1 g), -galactosidase plasmid (0.2 g), and either miR-control
(miR-C), miR-141, or miR-200a (100 nmol/l), and cells were analyzed
for -galactosidase and luciferase activity after 3 days. Both miR-141
and miR-200a were able to signiﬁcantly repress luciferase activity from
the TGF-23 UTR (*P < 0.05 compared with control transfected cells).
B: No activity of miR-141 and miR-200a against the mutant TGF-2
3UTR was observed. C: miR-141 and (D) miR-200a were able to
prevent the increased luciferase activity induced by TGF-1o nt h e
TGF-23 UTR. E: Total TGF-2 was signiﬁcantly decreased at the
protein level as measured by ELISA and (F) at the mRNA level as
measured by QPCR in NRK52E cells, 3 days after transfection with
miR-200a (*P < 0.05, compared with control).
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mal tubular cells were cotransfected with the luciferase
reporter constructs, a -galactosidase construct, and ei-
ther premiR-141, premiR-200a, or the premiR-control. This
experiment demonstrated that both miR-141 and miR-200a
directly repressed luciferase activity with the wild-type
3UTR of TGF-2 (Fig. 6A) but not with the mutant 3UTR
(Fig. 6B).
In separate experiments, cells were treated with TGF-1
4 h after transfection. TGF-1 signiﬁcantly increased lucif-
erase activity in cells transfected with the wild-type 3UTR
of TGF-2 and miR-control (Fig. 6C and D). These data are
consistent with our earlier observations demonstrating
increased expression of TGF-2 in response to TGF-1
(Fig. 2B). When TGF-1-treated cells were also transfected
with either miR-141 (Fig. 6C) or miR-200a (Fig. 6D), the
TGF-1-induced increase in luciferase activity in cells with
the wild-type 3UTR of TGF-2 was abolished. Consistent
with these observations, transfection of cells with miR-
200a reduced the expression of TGF-2 gene and total
TGF-2 protein levels as demonstrated by ELISA and
RT-PCR, respectively (Fig. 6E and F).
Decreased miR-141 and miR-200a in the kidneys from
diabetic mice. To further explore the relationship be-
tween miRNAs and diabetic kidney disease, we examined
the expression of miR-141 and miR-200a in the cortex of
kidneys from diabetic apoE KO mice. In this model, the
combination of chronic hyperglycemia and dyslipidemia
results in augmented renal ﬁbrosis (14), similar to that
seen in early diabetic renal disease in humans. As previ-
ously described, diabetes was associated with increased
protein expression of SMA, ﬁbronectin, and Col IV when
compared with nondiabetic controls (Fig. 7A). Real-time
quantitative PCR (QPCR) conﬁrmed changes in SMA, Col
IV, and ﬁbronectin mRNA levels (Fig. 7B). In addition, a
1.6-fold increase in TGF-1 and a 2.8-fold increase in
TGF-2 mRNA (Fig. 7C) were also observed in the cortex
of kidneys from diabetic mice. Consistent with these
changes, the gene expression levels of both miR-141 and
miR-200a were also signiﬁcantly reduced (Fig. 7D). Nota-
bly, the relative abundance of miR-200a was about 8–22-
fold higher than that of miR-141 in tubular cells and kidney
cortex (Fig. 7E).
Decreased miR-141 and miR-200a in advanced kidney
disease. In further experiments we investigated the ex-
pression of ECM genes and miR-141/200a in the advanced
renal disease associated with adenine-induced renal ﬁbro-
sis. As previously described, exposure to adenine resulted
in marked tubulointerstitial ﬁbrosis (Fig. 8A, right panel)
associated with a massive upregulation in the expression
of ECM genes as well as the ﬁbrogenic mediators TGF-1
and TGF-2 (Fig. 8B). Consistent with our earlier in vitro
and in vivo observations, miR-200a was signiﬁcantly de-
creased (Fig. 8C). miR-141 was also signiﬁcantly reduced
in this model.
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FIG. 7. Changes in gene and miR-200a expression in diabetic mouse kidney cortex. A: Immunohistochemical analysis demonstrated increased
expression for SMA, collagen IV (Col IV), and ﬁbronectin (Fibr) in the diabetic mouse kidney cortex compared with control. B: mRNA was
extracted from the renal cortex of control and 10-week diabetic apoE mice (n  8 per group). Gene expression was assessed by real-time QPCR
for a number of genes, revealing signiﬁcantly increased expression of SMA, ﬁbronectin, and collagen IV at the RNA level (*P < 0.01 and #P <
0.05 compared with control). C: Expressions of TGF-1 and TGF-2 were also elevated at the mRNA level in diabetic mouse kidney cortex (*P <
0.05 and #P < 0.01 compared with control). D: The increased expressions of TGF-1 and TGF-2 were associated with decreased expressions of
miR-141 and miR-200a in diabetic kidney (*P < 0.05 compared with control). E: Relative expression levels of miR-141 and miR-200a in NRK52E
cells and mouse kidney cortex. (*P < 0.005 compared with control). (A high-quality color representation of this ﬁgure is available in the online
issue.)
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MicroRNAs are now recognized to be key regulators of a
number of important developmental, homeostatic, and
pathogenic pathways. In this study, we demonstrate that
miR-200a and miR-141 impact on the development and
progression of TGF--dependent EMT and ﬁbrosis in vitro.
In particular, miR-200a and miR-141 are shown to be direct
translational repressors of TGF-2 by targeting the 3UTR
of this gene, as shown by experiments using a wild-type
TGF-23 UTR-luciferase construct. Furthermore, it was
also demonstrated that miR-200a could prevent the TGF-
1-induced expression of TGF-2 and other proﬁbrotic
changes, suggesting that it is an important downstream
regulator of TGF-1 signaling. Consistent with these ﬁnd-
ings in vitro, in early and more advanced models of kidney
disease, the downregulation of both miR-200a and miR-141
were also associated with increased TGF- expression and
renal scarring.
Although a number of different factors contribute to
renal scarring in the diabetic kidney, the best known and
most studied prosclerotic mediator is TGF- (6), which is
increased in the diabetic kidney (9). Although all isoforms
may have proﬁbrotic actions in vitro, recent data points to
the selective and predominant elevation of TGF-2a s
being particularly important in the diabetic kidney (8,11).
In both our early and advanced models of renal ﬁbrosis,
the expression of TGF-2 was markedly increased. Recent
studies have demonstrated that speciﬁc targeting of
TGF-2 attenuates the development of renal ﬁbrosis in
diabetic models (6,10). Consistent with this hypothesis, we
were able to reduce ﬁbrogenesis in vitro, with a neutraliz-
ing antibody to TGF-2 or alternatively by repressing
TGF-2 translation with miR-200a and miR-141.
EMT of mature tubular epithelial cells in the kidney
(also known as type 2 EMT) (23) is now recognized as a
contributor to the renal accumulation of matrix protein
associated with diabetic nephropathy and is fundamen-
tally linked to the progression of renal interstitial ﬁbrosis.
Recent evidence has demonstrated that a proportion of
interstitial ﬁbroblasts, the principal effector cells in this
process, are derived from tubular epithelial cells in the
diseased kidney via EMT (24). Furthermore, blockade of
speciﬁc steps of EMT dramatically reduces ﬁbrotic lesions
in a number of models of kidney ﬁbrosis, including diabe-
tes, highlighting the important role of EMT in nephropa-
thy. Although multiple signaling pathways and factors may
play a role in different aspects of EMT, its most potent
inducer is TGF-1, which is able to initiate and complete
the entire EMT process via SMAD recruitment as well as
via non-SMAD pathways (4,25). In this study, we show that
these actions require the induction of TGF-2 after the
downregulation of its translational repressors, miR-200a
and miR-141. Although these studies have been performed
in immortalized cells, in which expression of miRs and
their targets may be different from primary cells lines,
these ﬁndings are consistent with previous studies that
have identiﬁed the miR-200 family of microRNAs as regu-
lators of the epithelial cell phenotype and inhibitors of
EMT in tumor models (12,19,20,26) and that point to
miR-200a, in particular, as an important new target for the
prevention of renal ﬁbrogenesis. Given that reduced miR-
200a levels are associated with increased ECM expression,
and that restoring expression of miR-200a prevents many
of the ﬁbrotic changes in proximal tubular cells, miR-200a
appears to play an important role in ECM accumulation
and ﬁbrosis. Indeed, the ability of miR-200a to attenuate
SMAD3 activation has potential implications and could
prove an attractive option for targeting ﬁbrotic pathways
at different levels.
Although we have shown that miR-200a and miR-141
speciﬁcally target the 3UTR of TGF-2, it is well known
that some miRs are promiscuous and may bind the UTR
regions of a number of different targets. Interaction with
these other targets also has the potential to modify the
responses to miRs observed in this study. For example,
another important target of the miR-200 family are ZEB1
and ZEB2, themselves transcriptional repressors of E-
cadherin in epithelial cells. By repressing the translation of
ZEB1/2 in tumor models, the miR-200 family has been
shown to protect epithelial cells against the action of
pro-EMT factors such as TGF-1 and promote mesenchy-
mal-to-epithelial transition (1,12). We have previously
shown that another microRNA family, miR-192/215, which
also acts as a translational repressor of ZEB2, does not
modulate the expression of matrix proteins in response to
TGF-1 (17). Furthermore, mir-141 and miR-200a may not
only work as translational repressors of target mRNAs,
because they also caused a decrease in TGF-2 mRNA
levels. These ﬁndings conﬁrm recent data demonstrating
that some miRNAs can alter the mRNA levels of target
genes (3). This ability is probably independent of the
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FIG. 8. Changes in miR-141/200a expression in the kidney in the
adenine-induced renal ﬁbrosis model. A: Trichrome staining of tissue
sections from renal cortex from control and adenine-fed C57bl6 mice
after 4 weeks of treatment. Blue staining indicates high levels of
collagen in the adenine-fed mouse kidney compared with control. B:
mRNA was extracted from the renal cortex of control and adenine-fed
C57bl6 mice (n  4 per group). Gene expression was assessed by
real-time QPCR, revealing signiﬁcantly increased expression of colla-
gen I, collagen III, ﬁbronectin, vimentin, TGF-1, and TGF-2. C: The
increased expression of TGF-1, TGF-2, and collagen was associated
with decreased expression of miR-141 and miR-200a but not the
appropriate control, RNU6B, in kidney cortex (*P < 0.05 compared
with control). (A high-quality color representation of this ﬁgure is
available in the online issue.)
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target mRNAs.
At ﬁrst glance, miRNA-200a would appear to be an
attractive option for targeting renal ﬁbrosis. Yet, while
miR-200a exhibited signiﬁcant antiﬁbrotic effects in trans-
fected cells, the therapeutic means of achieving this in
vivo remain to be established, and the potential for off-
target effects is considerable. Modulation of miRNAs using
antisense inhibitors to block or mimics to enhance their
activity may be one option, while other researchers are
working on selective small-molecule inhibitors/activators
of miRNA ligation. It is likely that better understanding of
the role and activities of these antiﬁbrotic miRNAs will
provide novel means to inhibit renal ﬁbrogenesis including
in the context of diabetes.
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